AEZS vs. BCAB, FGEN, CALC, CMMB, ELEV, RLMD, OVID, NNVC, DRRX, and LSTA
Should you be buying Aeterna Zentaris stock or one of its competitors? The main competitors of Aeterna Zentaris include BioAtla (BCAB), FibroGen (FGEN), CalciMedica (CALC), Chemomab Therapeutics (CMMB), Elevation Oncology (ELEV), Relmada Therapeutics (RLMD), Ovid Therapeutics (OVID), NanoViricides (NNVC), DURECT (DRRX), and Lisata Therapeutics (LSTA). These companies are all part of the "pharmaceutical products" industry.
Aeterna Zentaris vs. Its Competitors
Aeterna Zentaris (NASDAQ:AEZS) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.
Aeterna Zentaris has higher earnings, but lower revenue than BioAtla. BioAtla is trading at a lower price-to-earnings ratio than Aeterna Zentaris, indicating that it is currently the more affordable of the two stocks.
BioAtla has a net margin of 0.00% compared to Aeterna Zentaris' net margin of -760.32%. Aeterna Zentaris' return on equity of -83.45% beat BioAtla's return on equity.
BioAtla has a consensus price target of $5.00, suggesting a potential upside of 1,180.41%. Given BioAtla's stronger consensus rating and higher possible upside, analysts plainly believe BioAtla is more favorable than Aeterna Zentaris.
0.7% of Aeterna Zentaris shares are held by institutional investors. Comparatively, 77.2% of BioAtla shares are held by institutional investors. 0.1% of Aeterna Zentaris shares are held by company insiders. Comparatively, 11.5% of BioAtla shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, BioAtla had 1 more articles in the media than Aeterna Zentaris. MarketBeat recorded 2 mentions for BioAtla and 1 mentions for Aeterna Zentaris. BioAtla's average media sentiment score of 1.87 beat Aeterna Zentaris' score of 0.67 indicating that BioAtla is being referred to more favorably in the news media.
Aeterna Zentaris has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, BioAtla has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500.
Summary
BioAtla beats Aeterna Zentaris on 10 of the 16 factors compared between the two stocks.
Get Aeterna Zentaris News Delivered to You Automatically
Sign up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AEZS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aeterna Zentaris Competitors List
Related Companies and Tools
This page (NASDAQ:AEZS) was last updated on 7/2/2025 by MarketBeat.com Staff
Free AEZS Stock Alerts